2 results
Approved WMOCompleted
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
Approved WMOCompleted
The primary objective of this study is to determine the sensitivity of the marker bevacizumab-IRDye800CW using innovative NIR fluorescence endoscopy (visualizing with wide-field endoscopy, measuring with MDSFR/SFF spectroscopy and optionally…